---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-093614"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2024-08-28T23:59:59+00:00"
generated_at: "2026-05-31T07:14:06.070912+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics faces Nasdaq delisting over bid price and equity deficiencies; hearing Oct 1

## Summary
- Minimum Bid Price Deficiency Letter received Aug 13; stock below $1.00 for 30 consecutive days through Aug 12.
- Not eligible for compliance period due to two reverse stock splits in past two years with cumulative ratio >250:1.
- Stockholders' Equity Deficiency Letter received Aug 15; equity at June 30, 2024 was $1,322,274, below $2.5M requirement.
- Raised ~$2.4M in July 2024 equity offering; pro forma equity ~$3.7M, but no assurance Staff will accept pro forma.
- Nasdaq Hearing Panel will consider appeal on October 1, 2024; delisting action stayed pending decision.

## SEC filing metadata
- accession: 0001104659-24-093614
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2024-08-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465924093614/0001104659-24-093614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465924093614/tm2422872d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-093614
- JSON: https://secwatch.observer/filing/0001104659-24-093614.json
- Plain text: https://secwatch.observer/filing/0001104659-24-093614.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.